SlidesetHIVHIV DART and Emerging Viruses 2018Abstract: Prevalence of neuropsychiatric conditions among HIV positive compared to HIV negative commercially insured individuals in 2017 NAFLD with dyslipidemia (#5) | Joshua Cohen, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Cytotoxic agents | Markus Jörger, MD, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Targeted agents and monoclonal antibodies | Joseph Ciccolini, PharmD, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: Correlation between nivolumab exposure and treatment outcome in NSCLC (#O1) | Sander BinsView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: The relationship between busulphan AUC and the incidence of sinusoidal obstruction syndrome in haematopoietic stem cell transplants (#O9) | Parth UpadhyayView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: Translation from mouse to human of pharmacokinetic-pharmacodynamic modelling of biomarker response – learnings from the AstraZeneca Oncology portfolio (#10) | Rhys JonesView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Clinical relevance of liquid biopsy in cancer patients | Catherine Alix-Panabières, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018How studies can be optimized by simultaneous use of PK/PD outcome measurement? | Alwin Huitema, PharmD, PhDView Slideset
MRMichelle RudekPharmD, PhDSlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: A generalisable pharmacokinetic-pharmacodynamic (PKPD) model of savolitinib, a novel MET tyrosine kinase inhibitor, to explore extent and duration of target inhibition required for optimal efficacy across a range of tumour xenograft models (#O8)View Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: A Pharmacokinetic-Pharmacodynamic binding model of Bevacizumab to VEGF as a tool to optimize treatment (#07) | Apostolos PapachristosView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: Novel online drug-drug interaction resource reveals clinically relevant interactions in >20% of the searches (#05) | Stefanie KrensView Slideset
